Peter Lachmann

Q: What Schools Are Affiliated With Peter Lachmann

Peter Lachmann is affiliated with the following schools: Harvard University, University of Cambridge, Stockholm University, Institute of Cancer Research, Weizmann Institute of Science, University College London, Royal Postgraduate Medical School

Peter Lachmann's AcademicInfluence.com Rankings

Peter Lachmann

Biology

#1277

World Rank

#2169

Historical Rank

Immunology

#83

World Rank

#89

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Peter Lachmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Peter Julius Lachmann was a British immunologist, specialising in the study of the complement system. He was emeritus Sheila Joan Smith Professor of Immunology at the University of Cambridge, a fellow of Christ's College, Cambridge and honorary fellow of Trinity College, Cambridge and of Imperial College. He was knighted for service to medical science in 2002.

(See a Problem?)

Peter Lachmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells (1989) (601)
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. (1990) (533)
Systemic lupus erythematosus, complement deficiency, and apoptosis. (2000) (526)
Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. (1985) (435)
Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. (1985) (275)
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen‐ and antigen‐stimulated human peripheral blood mononuclear cell cultures (1995) (260)
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell (1994) (250)
THE LOCALIZATION OF IN VIVO BOUND COMPLEMENT IN TISSUE SECTIONS (1962) (244)
AIDS--an immunologic reevaluation. (1984) (239)
REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS (1970) (236)
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. (1996) (236)
Specificity of membrane complement receptor type three (CR3) for beta-glucans. (1987) (221)
Bee venom immunotherapy induces a shift in cytokine responses from a TH‐2 to a TH‐1 dominant pattern: comparison of rush and conventional immunotherapy (1995) (203)
The effect of antibody isotype and antigenic epitope density on the complement‐fixing activity of immune complexes: a systematic study using chimaeric anti‐NIP antibodies with human Fc regions (1991) (194)
The amplification loop of the complement pathways. (2009) (190)
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. (1991) (188)
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. (1968) (186)
The control of homologous lysis. (1991) (185)
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies (1982) (180)
The physiological breakdown of the third component of human complement. (1980) (173)
Membrane defence against complement lysis: The structure and biological properties of CD59 (1993) (159)
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. (1994) (155)
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. (1985) (141)
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone (1996) (139)
Deficiency of C3 inactivator in man. (1971) (137)
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). (1973) (136)
REACTIVE LYSIS: THE COMPLEMENT-MEDIATED LYSIS OF UNSENSITIZED CELLS (1970) (133)
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. (1975) (130)
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. (1974) (129)
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes (2001) (126)
Conglutinin and immunoconglutinins. (1967) (125)
Universal health coverage and intersectoral action for health: key messages from Disease Control Priorities, 3rd edition (2017) (118)
Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)‐prone NZB/NZW mice by a new radial enzyme diffusion assay (1997) (115)
Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. (1996) (112)
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. (1976) (111)
Streptococcal Inhibitor of Complement Inhibits Two Additional Components of the Mucosal Innate Immune System: Secretory Leukocyte Proteinase Inhibitor and Lysozyme (2002) (109)
Complement-mediated adipocyte lysis by nephritic factor sera (1993) (106)
Identification of an anti‐monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1) (1984) (106)
Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. (1988) (102)
Initiation of complement activation (2005) (99)
Inherited deficiencies of the terminal components of human complement. (1992) (94)
Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. (1976) (94)
Reaction mechanism of the alternative pathway of complement fixation. (1973) (93)
Venom‐specific IgG antibodies in bee and wasp allergy: lack of correlation with protection from stings (1993) (92)
Identification of Ss protein as murine C4 (1975) (92)
Measles virus receptor on human T lymphocytes (1975) (88)
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. (1984) (87)
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein‐Barr virus transformation of the cells (1978) (86)
The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth and seventh components of human complement (C567) prepared in free solution by the 'reactive lysis' procedure. (1970) (85)
Three rat monoclonal antibodies to human C3. (1980) (83)
Allotypes of Complement Components in Man (1976) (83)
A library of oligosaccharide probes (neoglycolipids) from N-glycosylated proteins reveals that conglutinin binds to certain complex-type as well as high mannose-type oligosaccharide chains. (1989) (82)
INHERITED STRUCTURAL VARIATION AND LINKAGE RELATIONSHIPS OF C7 (1978) (81)
The breakdown of embryonic (chick) cartilage and bone cultivated in the presence of complement-sufficient antiserum. 3. Immunological analysis. (1966) (80)
Polymorphism of Human C6 (1975) (80)
Inactivator of the third component of complement as an inhibitor in the properdin pathway. (1972) (79)
Functional and antigenic similarities between a 94-kD protein of Schistosoma mansoni (SCIP-1) and human CD59 (1994) (79)
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. (1973) (78)
A second case of human C3b inhibitor (KAF) deficiency. (1977) (78)
The paraproteins in systemic capillary leak syndrome (1993) (75)
The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins (2004) (74)
Renin lineage cells repopulate the glomerular mesangium after injury. (2015) (72)
Preparing serum for functional complement assays. (2010) (72)
Complement studies in membrano-proliferative glomerulonephritis. (1972) (72)
Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. (1987) (71)
Fluorescent Protein Tracing: 2nd edn. (1965) (71)
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. (1973) (69)
New biological activity following intravascular activation of the complement cascade (1974) (69)
Activation of complement by Schistosoma mansoni schistosomula: killing of parasites by the alternative pathway and requirement of IgG for classical pathway activation. (1979) (68)
The immunological specificity of a macrophage inhibition factor. (1970) (67)
Transport of proteins into chloroplasts. Binding of nuclear-coded chloroplast proteins to the chloroplast envelope. (1982) (67)
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation (1988) (67)
The immunogloblin nature of nephritic factor (NeF). (1978) (64)
The mechanism of action of the C3b inactivator (conglutinogen- activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b) (1975) (64)
Complement component C7. Assessment of in vivo synthesis after liver transplantation reveals that hepatocytes do not synthesize the majority of human C7. (1994) (64)
Correlation of antinuclear antibodies and nuclear staining patterns. (1961) (63)
Inherited deficiency of erythrocyte complement receptor type 1 does not cause susceptibility to systemic lupus erythematosus. (1987) (63)
Neutrophil Fcγ and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes (1997) (63)
Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. (1988) (62)
Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1 (1985) (62)
The structural basis for neutrophil inactivation of C1 inhibitor. (1989) (61)
Combined genetic deficiency of C6 and C7 in man. (1978) (61)
Regulation of Complement (1988) (60)
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. (1986) (60)
Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. (1990) (60)
Deficiency of the effector mechanisms of the immune response and autoimmunity. (1987) (58)
Differences between C4A and C4B in the handling of immune complexes: the enhancement of CR1 binding is more important than the inhibition of immunoprecipitation (1990) (57)
Interaction between Host Complement and Mosquito-Midgut-Stage Plasmodium berghei (2001) (57)
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. (1990) (56)
Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis (1990) (56)
Characterization of patients with an increased susceptibility to bacterial infections and a genetic deficiency of leukocyte membrane complement receptor type 3 and the related membrane antigen LFA-1. (1985) (55)
Subversion of the innate immune response by micro-organisms (2002) (55)
Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. (1992) (55)
Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. (2004) (54)
Complement and immunity to viruses (1997) (54)
The Grandmother Effect (2011) (54)
A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes (1995) (53)
Resolution and analysis of 'native' and 'activated' properdin. (1987) (53)
Dysfunctional C1-inhibitor(At), isolated from a type II hereditary-angio-oedema plasma, contains a P1 'reactive centre' (Arg444----His) mutation. (1988) (53)
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. (1968) (53)
Identification of Structural Features of Condensed Tannins That Affect Protein Aggregation (2017) (53)
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. (1975) (50)
Ultrastructure and composition of bovine conglutinin. (1986) (50)
Molecular basis of subtotal complement C6 deficiency. A carboxy-terminally truncated but functionally active C6. (1995) (49)
Bovine serum conglutinin is a lectin which binds non-reducing terminal N-acetylglucosamine, mannose and fucose residues. (1989) (48)
Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes. (1994) (48)
Deficiency of factor B of the complement system in sickle cell anaemia. (1976) (48)
Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection (2014) (46)
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. (1971) (45)
Complement before molecular biology. (2006) (45)
The complement‐inhibiting protein, Protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells (1991) (45)
Genetics of the complement system. (2008) (44)
Bispecific antibody: a tool for diagnosis and treatment of disease (1990) (44)
Bovine conglutinin is a collagen-like protein. (1984) (43)
Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement. (1988) (43)
Statistical issues in first‐in‐man studies (2007) (42)
Hereditary angio‐oedema: a review with particular reference to pathogenesis and treatment (1971) (42)
Studies on the terminal stages of complement lysis. (1973) (42)
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. (1970) (42)
Lectin pathway effector enzyme mannan‐binding lectin‐associated serine protease‐2 can activate native complement C3 in absence of C4 and/or C2 (2017) (41)
HEREDITARY ANGIO‐OEDEMA TREATED WITH E‐AMINOCAPROIC ACID (1969) (40)
Microbial subversion of the immune response (2002) (40)
Immunity deficiency in pathogenesis of glomerulonephritis. (1974) (40)
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK (2011) (39)
A family study of hereditary angioneurotic oedema. (1973) (39)
Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice (1978) (39)
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. (1966) (38)
C6: synthesis by the liver in vivo (1977) (38)
Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4. (1995) (38)
Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. (1972) (37)
Human clones with natural killer function can activate B cells and secrete B cell differentiation factors (1985) (37)
A comparison of some properties of bovine conglutinin with those of rabbit immuno-conglutinin. (1962) (36)
Taking Complement to the Clinic – has the Time Finally Come? (2009) (34)
Complement deficiencies and abnormalities of the complement system in systemic lupus erythematosus and related disorders. (1990) (33)
An attempt to characterize the lupus erythematosus cell antigen. (1961) (33)
Molecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies. (1996) (33)
A comparative study of IgG subclass antibodies in patients allergic to wasp or bee venom (1994) (33)
Attribution of the Various Inhibitory Actions of the Streptococcal Inhibitor of Complement (SIC) to Regions within the Molecule* (2005) (33)
THE ORIGIN OF AN ANTIGENIC ZONE SURROUNDING HELA CELLS CULTURED ON GLASS. (1964) (32)
Exploring the terminal region of the proton pathway in the bacterial nitric oxide reductase. (2009) (32)
Purification of cobra venom factor from phospholipase A contaminant. (1976) (32)
The failure to show a necessary role for C3 in the in vitro antibody response (1975) (32)
Inherited complement deficiencies. (1984) (31)
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59 (1992) (31)
C6-Deficiency in Rabbits (1970) (31)
Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. (1985) (30)
The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. (1990) (30)
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. (1979) (30)
Lymphosarcoma, cold urticaria, IgG1 monoclonal cryoglobulin and complement abnormalities. (2009) (30)
Novel cleavage products of the third component of human complement. (1980) (30)
Demonstration of T-cell and K-cell cytotoxicity against measles-infected cells in normal subjects, multiple sclerosis and subacute sclerosing panencephalitis. (1977) (29)
Lesions due to Complement in Lipid Membranes (1971) (29)
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. (1970) (29)
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. (1973) (29)
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. (1992) (29)
A physical map of the C6 and C7 complement component gene region on chromosome 5p13. (1993) (28)
Looking back on the alternative complement pathway. (2018) (28)
CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients (1996) (28)
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. (1965) (28)
An anti‐peptide antibody that recognizes a neo‐antigen in the CR1 stump remaining on erythrocytes after proteolysis (1992) (28)
Use of Monoclonal Anti‐C3 Antibodies to Characterise the Fragments of C3 that Are Found on Erythrocytes (1983) (27)
Streptococcal DRS (distantly related to SIC) and SIC inhibit antimicrobial peptides, components of mucosal innate immunity: a comparison of their activities. (2007) (26)
Substrate Control of Internal Electron Transfer in Bacterial Nitric-oxide Reductase* (2010) (26)
Heberden oration 1986. Complement--friend or foe? (1987) (26)
A sensitive assay for cellular hypersensitivity based on the uptake of radioactive colloidal gold. (1974) (26)
LINKAGE STUDIES WITH C6 (1977) (26)
TREATMENT OF SYSTEMIC CAPILLARY LEAK SYNDROME (1988) (25)
Binding of model immune complexes to erythrocyte CR1 facilitates immune complex uptake by U937 cells. (1989) (24)
Stem cell research—why is it regarded as a threat? (2001) (24)
Experimental confirmation of the C3 tickover hypothesis by studies with an Ab (S77) that inhibits tickover in whole serum (2018) (23)
Persistent and inducible neogenesis repopulates progenitor renin lineage cells in the kidney. (2017) (23)
IgG synthesis within the brain in multiple sclerosis and subacute sclerosing panencephalitis. (1979) (23)
Lupus and desoxyribonuclease (2003) (23)
Factor B of the Alternative Complement Pathway on Human Lymphocytes (1976) (23)
CHAPTER 4 – Complement (1979) (22)
Lymphocyte‐Associated Complement: Role of C8 in Certain Cell‐mediated Lytic Reactions (1974) (22)
Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells. (1984) (22)
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. (1970) (22)
Polymorphism of human C5 (1981) (22)
Immunology: Are complement lysis and lymphocytotoxicity analogous? (1983) (21)
Extracts of wheat gluten activate complement via the alternative pathway (1993) (21)
Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects (1992) (21)
Mutation of a single residue in the ba3 oxidase specifically impairs protonation of the pump site (2015) (21)
Allergic reactions, connective tissue, and disease. (1967) (21)
Public health and bioethics. (1998) (21)
Neutrophil lactoferrin release induced by IgA immune complexes can be mediated either by Fc alpha receptors or by complement receptors through different pathways. (1996) (21)
Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay. (1987) (21)
A two-stage indirect L.E. cell test. (1961) (20)
Molecular basis of the complement C7 M/N polymorphism. A neutral amino acid substitution outside the epitope of the allospecific monoclonal antibody WU 4-15. (1995) (20)
Immunological studies on the cerebrospinal fluid in neurological sarcoidosis (1985) (20)
Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. (2002) (20)
The profiles of interleukin (IL)‐2, IL‐6, and interferon‐gamma production by peripheral blood mononuclear cells from house‐dust‐mite‐allergic patients: a role for IL‐6 in allergic disease (1994) (20)
The complement system in renal diseases (2006) (20)
Inhibition of antimicrobial peptides by group A streptococci: SIC and DRS. (2006) (19)
Antibodies are produced to the variable regions of the external envelope glycoprotein of human immunodeficiency virus type 1 in chimpanzees infected with the virus and baboons immunized with a candidate recombinant vaccine. (1992) (19)
Religion—An evolutionary adaptation (2010) (19)
Study of the in vitro activation of the complement alternative pathway by Echinococcus granulosus hydatid cyst fluid (1995) (19)
Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells (2021) (19)
How partial C7 deficiency with chronic and recurrent bacterial infections can mimic total C7 deficiency: temporary restoration of host C7 levels following plasma transfusion (1996) (19)
The use of animals in research. (1992) (18)
Restoration of specific immunological virginity (1974) (18)
A synthetic nonapeptide corresponding to the NH2-terminal sequence of C3d-K causes leukocytosis in rabbits. (1985) (18)
The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals (2012) (18)
Genetic deficiencies of the complement system. (1974) (18)
Further studies of the C3g component of the alpha 2D fragment of human C3. (1983) (18)
Further studies on the C3b inactivator or conglutinogen activating factor (KAF). (1973) (18)
Complotype affects the extent of down‐regulation by Factor I of the C3b feedback cycle in vitro (2015) (18)
Determination of CD59 protein in normal human serum by enzyme immunoassay, using octyl-glucoside detergent to release glycosyl-phosphatidylinositol-CD59 from lipid complex. (2003) (17)
Hopeful genes and immunology (1989) (17)
The Nitric-oxide Reductase from Paracoccus denitrificans Uses a Single Specific Proton Pathway* (2013) (17)
Immunoconglutinins and C3 in human saliva. (1975) (17)
Immunology: A common form of killing (1986) (17)
The use of antibodies in the prophylaxis and treatment of infections (2012) (17)
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3. (1989) (17)
Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope. (1993) (17)
A novel strategy for producing chimeric bispecific antibodies by gene transfection. (1989) (17)
A common form of killing (1986) (16)
The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus (2006) (16)
Specific selection of antigen-reactive lymphocytes into antigenically stimulated lymph nodes in sheep (1981) (16)
Antibody and complement in viral infections. (1985) (16)
Carrier Effect of Concanavalin A‐Reactive and ‐Non‐Reactive Material in Tuberculin PPD (1990) (16)
Metabolism of radio-labelled C3: effects of in vivo activation in rabbits. (1974) (16)
The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand. (1981) (16)
Timing of electron and proton transfer in the ba(3) cytochrome c oxidase from Thermus thermophilus. (2012) (16)
The relation of deoxyribonuclease inhibitor levels to the occurrence of antinuclear antibodies in NZB-NZW mice. (1972) (16)
Cellular immunity in subacute sclerosing panencephalitis. (1974) (16)
Intracerebral synthesis of antibodies to measles and distemper viruses in patients with subacute sclerosing panencephalitis and multiple sclerosis. (1980) (16)
Neutrophil lactoferrin release induced by IgA immune complexes differed from that induced by cross‐linking of Fcα receptors (FcαR) with a monoclonal antibody, MIP8a (2000) (16)
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. (1966) (16)
Immunological reactions at the cell surface. (1968) (15)
Migration inhibition factor secreting human T-cell lines reactive to PPD: a study of their antigen specificity, MHC restriction and the use of Epstein-Barr virus-transformed B-cell lines as requirement for antigen-presenting cells. (1984) (15)
Herpesvirus saimiri CD59--baculovirus expression and characterisation of complement inhibitory activity. (1997) (15)
Monoclonal antibodies which react with lymphocyte-lysed target cells and which cross-react with complement-lysed ghosts. (1985) (15)
Mechanisms of oligodendrocyte interaction with normal human serum - defining the role of complement (1992) (15)
Acquired C¯1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities (1976) (15)
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. (1979) (15)
The cofactors required by C3 nephritic factor to generate a C3 convertase in vitro. (1976) (14)
Complement deficiency and the pathogenesis of autoimmune immune complex disease. (1990) (14)
The story of complement factor I. (2019) (14)
The activation of the C3b feedback cycle with human complement components. I. Through the classical pathway. (1977) (14)
Structure of C3f, a small peptide specifically released during inactivation of the third component of complement. (1988) (14)
The quantitation of C6 in rabbit and human sera. (1971) (13)
Crystal‐ball gazing − the future of immunological research viewed from the cutting edge (2006) (13)
Lymphocyte traffic through lymph nodes during cell shutdown. (1980) (13)
Complement and Cell Membranes (1976) (13)
The use of antigen-antibody precipitates for specific detection of antigens in tissue sections. (1969) (13)
Paradoxical reconstitution of complement activity following plasma transfusion of an individual with deficiency of the seventh component of complement. (1994) (12)
Pre-steady-state kinetic characterization of thiolate anion formation in human leukotriene C₄ synthase. (2012) (12)
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. (1966) (12)
Universal health coverage and intersectoral action for health : key messages from Disease Control Priorities , 3 rd edition (2019) (12)
The Allotyping of Complement Components in Whole Serum by Iso-Electric Focusing in Gel followed by Specific Haemolytic Assay (1976) (12)
A competitive inhibition ELISA for the quantification of human interferon-gamma. (1993) (12)
Interference with Gsα-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial Damage. (2017) (12)
Anti-DNA antibodies in the urine of lupus nephritis patients. (1999) (12)
Structure of complement poly-C9 determined in projection by cryo-electron microscopy and single particle analysis. (1993) (12)
The in vivo destruction of antigen—a tool for probing and modulating an autoimmune response (1996) (12)
Complement component C6 and C7 haplotypes associated with deficiencies of C6 (1995) (11)
Antibodies raised to short synthetic peptides with sequences derived from HIV‐1 SF2 gp120 can both neutralize and enhance HIV‐1 SF13: A later variant isolated from the same host (2001) (11)
C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7 (1992) (11)
Complement receptors and cell associated complement components. (1977) (11)
Immunopathology of Measles (1974) (11)
AN ESTIMATE OF SOME MOLECULAR PARAMETERS OF BOVINE CONGLUTININ. (1964) (11)
Complement components on human lymphocytes. (1982) (11)
Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly. (1995) (10)
Studies with monoclonal antibodies to complement components. (1981) (10)
Structural homologies of component C5 of human complement with components C3 and C4 by neutron scattering. (1990) (10)
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. (1966) (10)
Difficulties in the ascertainment of C9 deficiency: lessons to be drawn from a compound heterozygote C9‐deficient subject (1997) (10)
E. Complement The immunochemistry of complement (1969) (10)
Peripheral blood mononuclear cells from house dust mite allergic patients produce IL‐2 in response to specific allergen challenge (1993) (10)
Complement genetics in relation to HLA. (1978) (10)
Health risks of genetically modified foods (1999) (10)
Microbial immunology: A new mechanism for immune subversion (1998) (10)
Subversion of the immune system by measles virus: a model for the intricate interplay between a virus and the human immune system. (2006) (9)
Polymorphism of the third component of canine complement (1981) (9)
Lymphocyte cooperation (1971) (9)
THE MIXED CONGLUTINATION REACTION. (1965) (9)
Cytostasis of different tumours by a murine PPD‐reactive CD4+ T lymphocyte clone is mediated by interferon‐gamma and tumour necrosis factor alone or synergistically (1990) (9)
Further studies of the down‐regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype (2016) (9)
C6–C7: A Further “Complement Supergene” (1978) (9)
Streptococcal infection in young pigs III. The immunity of adult pigs investigated by the bactericidal test (1969) (9)
Purification of antigen-dependent macrophage migration inhibition factor (MIF) from lymph draining a tuberculin reaction. (1978) (9)
Characterisation of the third component of canine and feline complement (1981) (9)
Comparison of C1q-receptors on rat microglia and peritoneal macrophages (1999) (9)
In vitro modulation of viral cell surface glycoproteins by anti-viral antibody in the presence of complement. (1982) (9)
The Killing of Tumour Cell Targets Coupled to Tuberculin (PPD) by Human and Murine PPD‐Reactive T Helper Clones (1988) (9)
Neuronal protection of oligodendrocytes from antibody‐independent complement lysis (1998) (8)
Genetic and Cultural Evolution: From Fossils to Proteins, and from Behaviour to Ethics (2010) (8)
The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice. (1981) (8)
Genetic Deficiency Diseases of the Complement System (1986) (8)
Towards a high-trust NHS : proposals for minimally-invasive reform (1996) (8)
Chicken Ovalbumin Upstream Promoter Transcription Factor II Regulates Renin Gene Expression* (2012) (8)
Tumour Immunology: A Review (1984) (8)
Consent and confidentiality—where are the limits? An introduction (2003) (8)
The detection and characterization of a membrane protein with Factor B-like activity on human lymphoid cells. (1981) (8)
Protection against complement lysis. (1990) (8)
Cell surface engineering using a complement regulatory molecule modified with a synthetic myristoyl-electrostatic switch derivative (1998) (8)
The catabolism of C1(-)-inhibitor and the pathogenesis of hereditary angio-edema. (1984) (8)
Anti-infective antibodies--reviving an old paradigm. (2009) (8)
Close linkage between mouse genes determining the two forms of complement component C6 and component C7, and cis action of a C6 Regulatory Gene (2004) (8)
Genetic defects of complement in man (1978) (8)
Universal Health Coverage and Intersectoral Action for Health (2017) (8)
Construction, expression and functional analysis of a glycolipid‐linked form of CR1 (1993) (8)
The failure to show a necessary role for C3 in the in vitro antibody response. (1975) (7)
The Killing of Tumour Cell Targets Coupled to Tuberculin (PPD) by Human and Murine PPD‐Reactive T Helper Clones (1988) (7)
Renin cells with defective Gsα/cAMP signaling contribute to renal endothelial damage (2019) (7)
Variable region (Fv) determinants on mouse lymphocytes. (1976) (7)
Complement genetics and host defence. (1990) (7)
Enzyme immunoassay detection of circulating immune complexes by monoclonal antibodies to C3 neoepitopes with special reference to IgG concentration and to interfering anti-immunoglobulin antibodies. (1989) (7)
The detection of Θ antigen on cells by immunofluorescence: Failure to detect Θ antigen on rosette‐forming cells (1972) (6)
Systemic ß adrenergic stimulation/ sympathetic nerve system stimulation influences intraocular RAS through cAMP in the RPE. (2019) (6)
Complement component C1q is sensitive to acute vitamin C defficiency in guinea pigs (1978) (6)
C6 haplotypes: associations of a Dde I site polymorphism to complement deficiency genes and the Msp I restriction fragment length polymorphism (RFLP) (1994) (6)
International collaborative study of four candidate reference preparations for the antigenic and hemolytic measurement of human serum complement components. (1981) (6)
The genetics of the sixth and seventh components of complement in the dog: Polymorphism, linkage, locus duplication, and silent alleles (1983) (6)
C7*N is a hypomorphic allele of the human complement c7 M/N protein polymorphism. (1991) (6)
Microbial subversion of immunity: current topics (2006) (5)
THE REVERSIBLE “DEDIFFERENTIATION” OF EMBRYONIC SKELETAL TISSUES IN CULTURE IN RESPONSE TO COMPLEMENT-SUFFICIENT ANTISERUM (1968) (5)
Receptors on guinea-pig erythrocytes specific for cell-bound fourth component of human complement (C4). (1980) (5)
Complement Polymorphism and Disease (1984) (5)
Genetics of the complement system. (1975) (5)
Nephrotic syndrome from penicillamine. (1968) (5)
C3 receptors, complement deficiency and SLE. (1984) (5)
Haemolytic assays in agarose plates for components of the classical complement pathway: interference by the alternative pathway. (1977) (5)
Production of MIF and mitogenic factor in vivo. (1973) (5)
Adeno-associated virus vector gene delivery elevates Factor I levels and down-regulates the complement alternative pathway in vivo. (2021) (5)
In vitro complement activation by rabbit lymphocytes and thymocytes in autologous serum. (1979) (5)
Complement and disease. (1988) (5)
A novel strategy for targeting CD4+ PPD‐reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates (1990) (5)
Linkage studies in hereditary angio-oedema. (1979) (4)
Purified protein derivative (PPD) (2005) (4)
Systemic Lupus Erythematosus (1967) (4)
Antibody-dependent cytotoxicity on chicken red blood cell targets mediated by the U937 cell line. (1987) (4)
ABSENCE OF VARIATION IN HUMAN C5 (1978) (4)
The coagglutination phenomenon of Bordet and Gengou involves a reaction between antibody-aggregated fourth component of complement and a receptor on guniea pig red cells. (1980) (4)
THE REACTION OF SODIUM AZIDE WITH FLUOROCHROMES. (1964) (4)
Circulating immune complexes in Indian childhood cirrhosis. (1982) (4)
A Possible Homeostatic Mechanism in Complement Fixation: Inhibition of the Activity of Fixed C′1 By The Fixation Of C′3a (1966) (4)
C1 INHIBITOR IN MALIGNANT DISEASES (1976) (4)
Complement in IgA immune-complex-induced neutrophil activation. (1997) (4)
Theimmunosuppressive drugthalidomide induces T helper cell type2(Th2) andconcomitantly inhibits Thlcytokine production inmitogen- and antigen-stimulat ed humanperipheral bloodmononuclear cell cultures (1995) (4)
GM food debate (1999) (4)
Restoration by Purified C 3 b Inactivator of Complement-Mediated Function In Vivo in a Patient with C 3 b Inactivator Deficiency (4)
Biological functions of the complement system. (1990) (3)
An efficient one-step method for isolating immune complexes from whole serum using a monoclonal anti-C3g affinity immunosorbent. (1986) (3)
A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung. (1985) (3)
The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate. (1992) (3)
Complement Today (1988) (3)
Soluble CD59 is present in human plasma (1993) (3)
A novel protein polymorphism of human complement C7 detected by a monoclonal antibody (2004) (3)
Immunology of leishmaniasis. (1993) (3)
The isolation of the antibody moieties of immune complexes from serum by the pepsin digestion of conglutinin-anti-conglutinin complexes. (1981) (3)
The activation of the C3b feedback cycle with human complement components. II. Using components of the alternative pathway. (1977) (3)
Update on BSE (1997) (3)
Plugs, burns and poisons. (1987) (3)
Derivatization of soluble human CD59 with a myristoylated peptide creates a potent membrane-bound inhibitor of complement-mediated lysis (2000) (3)
Identification of MIC 11 antigen as an epitope of the CD59 molecule. (1995) (3)
A NOVEL HUMAN COMPLEMENT COMPONENT C7 PHENOTYPE DETECTED IN SOUTH AFRICA AND PROPOSED DESIGNATION OF THE ALLELE AS C7*10 (1994) (3)
Genetics of complement. (1988) (2)
It's what not where you publish that matters (1998) (2)
TheImmunological Specificity ofaMacrophage Inhibition Factor (1970) (2)
The treatment of congenital adrenal hyperplasia with aminoglutethimide. (1971) (2)
The dysmorphic but functionally active C6 of subtotal C6 deficient subjects is carboxyterminally truncated (1993) (2)
Intestinal Glycoprotein Activates the Alternative Complement Pathway by Reacting with Factor H (1982) (2)
Massive C Activation: The Interactions of C and the Extrinsic Blood Coagulation System in the Production of Disseminated Intravascular Coagulation (1973) (2)
THE MECHANISM OF ACTION OF PROTECTIN (CD59), A HOMOLOGOUS RESTRICTION FACTOR OF THE HUMAN-COMPLEMENT SYSTEM (1990) (2)
Peptide inhibitors of C3 breakdown (1990) (2)
A novel and sensitive functional assay for complement Factor I based on the third proteolytic clip of C3b. (2018) (2)
Current topics in complement research. (1996) (2)
Antibody engineering: current status and future development. (1990) (2)
Three ratmonoclonal antibodies tohumanC3 (1980) (2)
Analysis of the interaction between properdin and Factor B , components of the alternative-pathway C 3 convertase of complement (2005) (2)
Studies ontheTerminal Stages ofComplement Lysis (1973) (2)
Ethics Evolve (2013) (2)
Robert Royston Amos (Robin) Coombs. 9 January 1921 — 25 January 2006 (2009) (2)
The membrane attack complex inhibitor of streptococcus pyogenes (SIC) binds preferentially to C567 (2000) (1)
Oligodendrocytes lackglycolipid anchored proteins whichprotect themagainst complement lysis. Restoration ofresistance tolysis byincorporation ofCD59 (1992) (1)
Abstracts of Papers Presented at the Third International Complement Workshop, Harvard Medical School, Boston, Massachusetts, June 3–5, 1968 Complement-Dependent Lysosomal Activation (1968) (1)
It is increased carriage on red cell c'R IND.1' and not solubilization that is the main function of complement in the handling of immunocomplexes (1989) (1)
Stem cell therapy: medical advance or moral challenge? (2002) (1)
Metabolism of C3 and Glycine-Rich β Glycoprotein (GBG) in Hypocomplementaemia (1974) (1)
CIBA FOUNDATION SYMPOSIUM (NEW SERIES) 46 (1977) (1)
Diet and Diseases : Facts and Fantasies (2005) (1)
Clinical aspects of immunology. Volume 3. (1993) (1)
Interactions between complement and the malaria parasite in the mosquito gut (1998) (1)
Xivth international complement workshop cambridge england uk september 15 20 1991 (1991) (1)
C6 epitope expression by an unrelated antisense cDNA clone: an inadvertent surface-simulation mimotope (1993) (1)
Book Review:The Plasma Proteins: Structure, Function, and Genetic Control. Frank W. Putnam (1986) (1)
GOD: "TO BE OR NOT TO BE; THAT IS NOT THE QUESTION" (2009) (1)
Immunology of the Gut (1978) (1)
Activation of Complement (C) in Human or Animal Serum by Lymphoblastoid Cell Lines Derived from Patients with Burkitt's Lymphoma (BL) and Infectious Mononucleosis (IM) (1976) (1)
A more radical solution. (2015) (1)
The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha-chain of the complement component, C3. (1989) (1)
An open letter to the health secretary: how to really save money on the NHS (2010) (1)
Factor B on Lymphoid Cells (1976) (1)
The Temporary Sequestration of C3-Coated Red Cells (EC43) in the RES of the Rabbit: A Mechanism for the Non-Lytic Damage of Red Cells by Complement (1971) (1)
A cleavable biotinylating agent and its use in protein electroblots. (1992) (1)
The immunology of helminth infections. (1993) (1)
Cellular Immunity in Subacute Sclerosing Panencephalitis (1974) (1)
Murine and human tuberculin reactive T helper clones: their role in anti-tumour immunity (1985) (1)
Clinical aspects of immunology, volumes 1 and 2. (1982) (1)
Molecular characterization of the genes for complement components c6 and c7 (1991) (1)
The elusive muscular dystrophy gene . Fifth Muscular Dystrophy Group Workshop on the X chromosome and muscular dystrophies , April 1986 (1)
The breakdown of C3bi to C3c, c3d and C3g (1982) (1)
Complement, Conglutinin and Immuno‐Conglutinins (2008) (1)
Stabilization by Vi polysaccharide of the red-cell-linked antigen—antiglobulin complex allowing identification of the Ig—type of the combined antibodies by means of specific antiglobulin reagents (1966) (1)
Evolution, ethics and religion (2014) (1)
Complotype affects the extent of down-regulation by Factor I of the C 3 b feedback cycle in-vitro 1 Short title : In-vitro effects of complotype (2014) (1)
Speaking ill of Darwin and Chomsky: The Kingdom of Speech: by Tom Wolfe: Little Brown & Co., New York, 2016. (2017) (1)
Editorial: the urgent need to reform the present system of medicines' regulation. (2015) (1)
Mechanisms of C3 Breakdown by Hypocomplementaemic Serum from Patients with Mesangiocapillary Nephritis (1974) (1)
Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency1 (2020) (1)
Microbial Subversion of Immunity (2007) (1)
Overview: parasitism and immunity. (1993) (1)
The Capacity of Lymphoblastoid Cells to Activate the Alternative Complement Pathway Is Correlated with their Transformation by Epstein-Barr Virus (1978) (1)
Thedetection andcharacterization ofamembraneprotein withFactor B-like activity onhumanlymphoid cells (1981) (0)
Contributions in Immunology (1976) (0)
Robert Royston Amos (Robin) Coombs. 9 (2016) (0)
Analysis of the restriction of lysis of sheep ea by horse serum (1987) (0)
A second caseofhumanC3binhibitor (KAF)deficiency (1977) (0)
Peter Lachmann (2003) (0)
Fractionation of Activated Reactor Absorption with Zymosan (4 mg/ml) and Precipitation as Euglobulin.-- (2003) (0)
S13.22 The mechanism of nitric oxide reduction in NOR from Paracoccus denitrificans (2008) (0)
Microbial Subversion of NK cell Function (2006) (0)
Molecular genetics of muscle disease--Duchenne and other dystrophies. Future prospects. (1989) (0)
Meeting review: complement today (1988) (0)
The interaction between rat olicodendrocytes and human complement in vitro (1991) (0)
Does complement play a role in mucosal immunity? (1988) (0)
A novel C3 fragment found in normal plasma and serum: Its implications for C3 tickover (2013) (0)
Vaccines – current status and future needs (2005) (0)
Euthanasisa : death, dying and the medical duty (1996) (0)
Evasion mechanisms of bacteria. (2006) (0)
The evolution of complement and the alternative pathway (2017) (0)
Health care: Better drug access for terminal patients (2013) (0)
A ring precipitin test in chronic liver disease: a study of the false positive. (1961) (0)
Dyscrasias of Immunoglobulin Production: Their Impact on Modern Immunology (1970) (0)
Biochemistry and genetics of complement : proceedings of a Royal Society discussion meeting held on 25 and 26 January, 1984 (1984) (0)
International Complement Workshop: 14th Workshop, Cambridge, September 1991: Abstracts (1991) (0)
Traditional passive immune therapy for emerging Ebola infection (2014) (0)
The PPAR-gamma-binding sequence Pal3 is necessary for basal but dispensable for high-fat diet regulated human renin expression in the kidney (2017) (0)
Interaction between complement and the malaria parasite in the mosquito vector (2000) (0)
Immunology of amoebiasis and giardiasis. (1993) (0)
Towards a CD59-based therapeutic: GPI anchor substitution with a membrane-targeting address (2001) (0)
Detection of a fragment ot the cr1 receptor on podolytes of sle proliferative glomerulonephritis (1992) (0)
Techniques of Fractionating Complement in-Vivo by the Use of Activated Complement Components to Trigger the C3b Feedback Cycle (1976) (0)
The Seventh K Prathap Memorial Lecture. The pathogenesis of autoimmune immune complex disease. (1992) (0)
Functional characterization of DRS from Streptococcus pyogenes M12 and M55 serotypes (2006) (0)
Complement, Alternative Pathway (1998) (0)
Properties ofa lowmolecular weightcomplementcomponent C6 foundinhumansubjects withsubtotal C6 deficiency (1992) (0)
Proceedings: Metabolism of C3 and glycine-rich beta glycoprotein (GBG) in hypocomplementaemia. (1974) (0)
Complement metabolism in membranoproliferative nephritis. (1971) (0)
THE NATURE OF AUTOIMMUNE-DISEASE - GENERAL DISCUSSION (1987) (0)
Simultaneous turnover ofnormal anddysfunctional C1inhibitor asaprobe ofinvivo activation ofC1and contact activatable proteases (1985) (0)
Editorial (Thematic Issue: The Urgent Need to Reform the Present System of Medicines’ Regulation) (2015) (0)
Nitric oxide dependent electron transfer and proton uptake in bacterial nitric oxide reductase (2010) (0)
Contents, Vol. 61, 1980 (1980) (0)
081A teenager with primary pneumococcal peritonitis (2017) (0)
Structural and functional features of herpesvirus saimiri CD59 (1998) (0)
Experimental aspects of systemic lupus erythematosus. (1967) (0)
Book Review: The Generation of Antibody Diversity: A New Look (1977) (0)
Conversion of the liver into a biofactory for DNaseI using adeno-associated virus vector gene transfer reduces neutrophil extracellular traps in a model of Systemic Lupus Erythematosus. (2022) (0)
The majority of human C7 synthesised in vivo is of extrahepatic origin (1993) (0)
Acquired Immunodeficiency Syndrome Progress in Allergy (2015) (0)
Preface (2013) (0)
Why Study Complement Genetics (1984) (0)
The biology of complement. Introduction. (1994) (0)
John Gordon-A greatly undervalued complement pioneer. (2018) (0)
The Lloyd Roberts Lecture. Immunopathology: past, present and future. (1999) (0)
Recent Advances in Our Knowledge of Complement (1987) (0)
Membrane Activation in Immunologically Relevant Cells Progress in Allergy Activation in Immunologically Relevant (2015) (0)
The immunology of African trypanosomiasis. (1993) (0)
The pathogenesis of autoimmune immune complex disease (2007) (0)
International Symposium on Immunological Tolerance (2004) (0)
Inhibition of alternative pathway convertase by rat monoclonal antibodies to human factor B (1982) (0)
Contents, Vol. 27, 1965 (1965) (0)
Cytolysis by Cloned Helper T Cells: Induction by Specific Antigen or by Anti‐CD3 Hybrid Antibodies (1988) (0)
The influence of infection on society (2018) (0)
Acknowledgements and Speaker Affiliations (2013) (0)
The Scientific Basis of Medicine (Annual Reviews, 1962) (1963) (0)
Subversion of complement. (2006) (0)
COMPLEMENT DEFICIENCIES (1975) (0)
Mapping of functional domains of streptococcal inhibitor of complement (SIC) (2006) (0)
A Defect of the Alternative Pathway of Complement in Sickle Cell Disease (1976) (0)
Allotyping of monocyte C3 (1982) (0)
Structure and functions of low affinity Fc receptors. (1989) (0)
Biological Amplification Systems in Immunology: Vol. 2 of Comprehensive Immunology (1978) (0)
Viruses and dendritic cells: a prominent mechanism for subverting the immune response. (2006) (0)
AN IATROGENICAUTOANTIBODY: IMMUNOLOGICAL RESPONSESTO 'PITUITARYSNUFF'IN PATIENTS WITH DIABETESINSIPIDUS (1966) (0)
Internationales Komplement Symposion 14. und 15. Juli 1969 in Mainz (1969) (0)
The Two Cultures at Cambridge (2018) (0)
THE QUANTITATION OF C6INRABBITAND HUMAN SERA (1971) (0)
Viral subversion of humoral immune responses. (2006) (0)
Renin gene expression is regulated by Chicken Ovalbumin Upstream Promoter Transcription Factor II (COUP‐TF II) (2013) (0)
Mucosal innate immune response. (2006) (0)
IMMUNOREGULATORY APPROACHES TO TREATMENT - FINAL GENERAL DISCUSSION (1987) (0)
Resistance to Antimicrobial Agents Response to the House of Lords Science and Technology Select Committee Inquiry (2000) (0)
Women in medicine: RCPath represented at conference (1993) (0)
Electron and Proton Transfer in Nitric Oxide Reductase : NO Binding, NO Reduction and no Pumping (2009) (0)
S11.31 Nitric oxide reductase from Paracoccus Denitrificans —what are the five conserved glutamates in norb good for? (2008) (0)
Kinetics of proton and electron transfer in heme-copper oxidases (2015) (0)
Henry Kunkel. (2003) (0)
Reaction-Mechanisms Of C3NeF (1976) (0)
The Immune Response in Subacute Sclerosing Panencephalitis (1979) (0)
Cd-59 like molecule in trypanosoma cruzi (1993) (0)
Medicine Development Needs Radical Reform: Commentary (2017) (0)
Viral immune evasion: an overview. (2006) (0)
Immunoconglutinins inHumanSaliva-A Group ofUnusual IgAAntibodies (1970) (0)
Cell adhesion and migration of different human colon cell lines and primary tumors (2004) (0)

This paper list is powered by the following services:

Other Resources About Peter Lachmann

en.wikipedia.org

What Schools Are Affiliated With Peter Lachmann?

Peter Lachmann is affiliated with the following schools: